Next Generation Newborn Screening for Congenital Hypothyroidism?
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Newborn screening for congenital hypothyroidism (CH) began in Quebec in 1974. Jean Dussault and Claude Laberge adapted newly available immunoassays for T4 and TSH and new information characterizing thyroid system ontogenesis in the fetus and newborn to the Quebec filter paper blood spot screening program for phenylketonuria (1–7). Parallel programs were rapidly developed in New England and the northwest United States, leading in 1977 to recommendations for CH screening programs from the Newborn Screening Committee of the American Thyroid Association and publication of results of screening of the first million infants in 1979 (8, 9). A progress report of results covering 489,868 infants screened in 36 centers from 12 European countries was published by the Newborn Committee of the European Thyroid Association in 1980 (10). By 1992 it was estimated that 50 million infants worldwide were screened yearly, and the diagnosis of CH was confirmed in 3000–4000 births (11). There have been continuing questions and studies of CH infants for the optimal dose and timing of replacement therapy with Na-l-T4 (12). Nevertheless, the screening programs have achieved the goal of early detection and therapy and normal or near-normal development of infants with the classical forms of primary CH comprising some 90% of CH infants (11, 13–15). The testing strategy has varied among programs with emphasis on detection of primary CH. The initial programs in North America employed a total T4 measurement followed by a TSH assay for specimens with low T4 values; European programs favor primary TSH screening (11, 16). Primary T4 screening is usually conducted using a follow-up TSH measured in infants with T4 values below arbitrary threshold levels. TSH is the most specific test for primary CH, but it does not detect infants with central hypothalamic-pituitary causes of CH. Total T4 measurements are less specific for primary or central CH. In Europe, due to the relatively low prevalence of central CH, it has been recommended that T4 not be included in the screening programs (16). The prevalence of central CH varies from 1:25,000 to 1:100,000 births (13). In the program in the northwest United States, where there is a concerted effort to identify all cases clinically, the prevalence is 1:29,000 births (13). Two-tiered testing (T4 + TSH) can identify suspect cases of central CH if low T4 and normal-low range TSH values are both reported (13). In 1986, Hanna et al. (18) reported 10-yr results from the northwest United States program adding a second screen at 6 wk of age to detect infants with CH missed during the first screening. Although detecting some missed cases of primary CH, central CH was identified in only 8 of 19 infants (11 identified by clinical means only) (18). Data for the 50 United States, the District of Columbia, and two territories summarized in the latest national newborn screening report (2000) on The National Newborn Screening and Genetics Resource Center web site (http://genes-r-us.uthscsa.edu) lists 41 states conducting primary T4 screening (T4 + TSH), three conducting primary TSH screening (TSH + T4), and nine conducting TSH alone screening (TSH). The total number of infants screened in the listing was 4,125,135, with detection of 1,635 neonates with primary CH (1:2,533 births), 43 with secondary CH (1:95,933 births), and 362 with transient CH (1:11,345 births). The incidences of primary and secondary CH among 653,129 infants screened by eight states conducting a requisite second screen were similar (1:2,533 for primary and 1:130,000 for secondary) to results in the 53 programs, suggesting that a second (T4 + TSH or TSH + T4) screen does not improve detection of central CH. One of the reasons for the low sensitivity of T4 in the detection of CH is that total T4 measurements largely represent T4 bound to T4 binding globulin (TBG) and, to a lesser extent, albumin and transthyretin (prealbumin). Thus, developmental, genetic, or disease-related variations in TBG artifactually alter T4 concentrations. Free or dialyzable T4 is more specific for the diagnosis of CH. However, free T4 measurements require relatively large serum samples and are not applicable to filter paper samples. One surrogate for free T4 is measurement of the T4/TBG ratio, which has been employed in the Netherlands CH screening program since 1995 (19). In that program, measurement of TBG is conducted in the lowest 5% of T4 values in a three-tier T4, TSH, TBG system; TSH is measured in the lowest 20% of T4 values. The T4/TBG ratio is calculated as T4 (in sd) + 5.1/TBG (in nanomoles per liter serum). A second heel stick filter paper blood sample is collected in cases with a borderline T4 and a low T4/TBG ratio and/or a borderline TSH concentration (19). Using this approach, all known infants with primary CH (n = 393) in the first 1,181,079 infants screened between January 1995 and December 2000 and 92% (66 of 72) of infants with central CH were detected (19)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neonatal Detection of Congenital Hypothyroidism of Central Origin
van Tijn, D. A., de Vijlder, J. J. M., Verbeeten, B., Verkerk, P. H., & Vulsma, T. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2444 · Cited by 139
Cited by
Léger, J., Olivieri, A., Donaldson, M., Torresani, T., Krude, H., van Vliet, G., Polak, M., Butler, G., & on behalf of ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE, A. T. C. H. C. C. G. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1891 · Cited by 569
Léger, J., Olivieri, A., Donaldson, M., Torresani, T., Krude, H., van Vliet, G., Polak, M., Butler, G., & on behalf of ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE, A. T. C. H. C. C. G. (2014) · Hormone Research in Paediatrics · doi:10.1159/000358198 · Cited by 208
Recent advances in central congenital hypothyroidism
Schoenmakers, N., Alatzoglou, K. S., Chatterjee, V. K., & Dattani, M. T. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0341 · Cited by 125
“Additional modulators of TSH secretion include hypothalamic dopamine and somatostatin (inhibitory), and the influence of feeding behaviour, glucocorticoids, severe illness, cold, and circadian rhythm (Fliers et al. 2006).”
BackgroundKempers, M. J. E., Lanting, C. I., van Heijst, A. F. J., van Trotsenburg, A. S. P., Wiedijk, B. M., de Vijlder, J. J. M., & Vulsma, T. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0058 · Cited by 109
The Severity of Congenital Hypothyroidism of Central Origin Should Not Be Underestimated
Zwaveling-Soonawala, N., van Trotsenburg, A. S. P., & Verkerk, P. H. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2871 · Cited by 49
Metadata
- Authors
- Fisher, D.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-06
- Volume
- 90
- Issue
- 6
- Pages
- 3797-3799
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2118991511
- Cited by
- 22
- References
- 1
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.